Filtered By:
Drug: Taxotere
Countries: Canada Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19 results found since Jan 2013.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT02446405, ANZCTR, ACTRN12614000110684, and EudraCT, 2014-003190-42.FINDINGS: Between March 31, 2014, and March 24, 2017, 1125 participants were randomly assigned to receive non-steroidal antiandrogen (n=562; control group) or enzalutamide (n=563). The median age was 69 years (IQR 63-74). This analysis was triggered on Jan 19, 2022, and an updated survival status identified a total of 476 (42%) deaths. After a median follow-up of 68 months (IQR 67-69), the median overall survival was not reached (hazard ratio 0·70 [95% CI 0·58-0·84]; p<0·0001), with 5-year overall ...
Source: Cancer Control - March 29, 2023 Category: Cancer & Oncology Authors: Christopher J Sweeney Andrew J Martin Martin R Stockler Stephen Begbie Leanna Cheung Kim N Chi Simon Chowdhury Mark Frydenberg Lisa G Horvath Anthony M Joshua Nicola J Lawrence Gavin Marx John McCaffrey Ray McDermott Margaret McJannett Scott A North Franc Source Type: research
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer
CONCLUSION: In this large, multicenter retrospective chart review of patients with KRAS G12C mutant NSCLC we observed a relatively short median rwPFS of 4.6 months among 10 patients with KRAS G12C mutant NSCLC treated with docetaxel with or without ramucirumab in the second-line setting, which aligns with the recently reported CodeBreak 200 dataset.PMID:36841727 | DOI:10.1016/j.cllc.2023.01.009
Source: Clinical Lung Cancer - February 25, 2023 Category: Cancer & Oncology Authors: Wade T Iams Meridith L Balbach Sharon Phillips Adrian Sacher Christine Bestvina Vamsidhar Velcheti Xiao Wang Melina E Marmarelis Nan Sethakorn Ticiana Leal Paul E Sackstein Chul Kim Md Andrew Robinson Kathan Mehta Robert Hsu Jorge Nieva Tejas Patil D Ross Source Type: research
Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic
CONCLUSION: Management of patients with mHSPC in Canada has changed during the pandemic, with increased uptake of ARATs and reduced use of docetaxel, a trend expected to continue beyond the pandemic. How this trend will impact uptake of triplet therapy (ADT + ARAT + Docetaxel), downstream treatment choices and overall outcomes remains to be seen.PMID:36621461 | DOI:10.1016/j.clgc.2022.11.020
Source: Clinical Prostate Cancer - January 9, 2023 Category: Cancer & Oncology Authors: Carlos E Stecca Di Maria Jiang Zachary Veitch Sebastian J Hotte Nimira Alimohamed Lori Wood Srikala S Sridhar Source Type: research
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer
CONCLUSIONS: DR following chemohormonal therapy for mCSPC produced a meaningful PSA response in approximately one-quarter of patients, with relatively short PFS. The impact of Gleason Score on docetaxel response warrants further investigation.PMID:36272847 | DOI:10.1016/j.urolonc.2022.09.010
Source: Urologic Oncology - October 22, 2022 Category: Urology & Nephrology Authors: Mary Mahler Esmail Al-Ezzi Noa Shani Shrem Liying Zhang Eric Winquist Christina Canil Michael Ong Aaron R Hansen Urban Emmenegger Source Type: research
Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI
CONCLUSIONS: In a real-world mCRPC cohort, cabazitaxel use was associated with longer OS among PAR patients, but crucially not among strong ARPI responders. Cabazitaxel was used less frequently and later than ARPIs post-docetaxel. These data help support first ARPI progression time as a consideration in treatment sequencing.PMID:35599196 | DOI:10.1016/j.clgc.2022.04.009
Source: Clinical Prostate Cancer - May 22, 2022 Category: Cancer & Oncology Authors: Alexander S Watson Richard Gagnon Eugene Batuyong Nimira Alimohamed Richard Lee-Ying Source Type: research
A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer
CONCLUSIONS: We found that 223Ra therapy can result in an OS of close to two years in carefully selected patients. Earlier administration of 223Ra therapy to fitter patients with mCRPC should be tested.PMID:35099384 | DOI:10.5489/cuaj.7591
Source: Canadian Urological Association Journal - January 31, 2022 Category: Urology & Nephrology Authors: C édric Charrois-Durand Fred Saad Maroie Barkati Jean-Baptiste Lattouf Paul Perrotte Pierre I Karakiewicz Denis Souli ères Normand Blais Zineb Hamilou Daniel Juneau Nicolas Plouznikoff Daniel Taussky Guila Delouya Source Type: research
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
CONCLUSION: The primary endpoint of superiority of G-CSF over ciprofloxacin was not demonstrated. While there were reduced FN rates with G-CSF, there were no differences in chemotherapy dose delays/reductions or discontinuations. With the commonly used willingness to pay value of C$50,000/QALY, G-CSF use was not cost-effective compared to ciprofloxacin and deserves scrutiny from the payer perspective.PMID:33901921 | DOI:10.1016/j.breast.2021.03.012
Source: Breast - April 26, 2021 Category: Cancer & Oncology Authors: Mark Clemons Dean Fergusson Anil A Joy Kednapa Thavorn Judith Meza-Junco Julie Price Hiller John Mackey Terry Ng Xiaofu Zhu Mohammed F K Ibrahim Marta Sienkiewicz Deanna Saunders Lisa Vandermeer Gregory Pond Bassam Basulaiman Arif Awan Lacey Pitre Nancy A Source Type: research
